Envisia Therapeutics Names Eric Linsley Chief Financial Officer

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Envisia Therapeutics today announced that it has named Eric Linsley as the Company's Chief Financial Officer. Prior to Envisia, Mr. Linsley was a managing partner at Pappas Ventures in Durham, NC where he was directly responsible for investments that led to several very successful acquisitions and public offerings. He brings with him more than 20 years of experience and a proven track record of finance and life science investment expertise.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.